Article

Urology Times, Digital Edition, August 2011

Related Videos
Drug costs | Image Credit: © pixelrobot - stock.adobe.com
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
1 expert in this video
Related Content
Urologists perform first remote robot-assisted HIFU for prostate cancer
April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke
“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
April 17th 2025

Exploring new avenues in non–muscle invasive bladder cancer treatment

Urology Times staff
Three recent expert-led Clinical Forums explored current challenges and advancements in the management of non–muscle invasive bladder cancer.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Neuromodulation device shows promising efficacy for neurogenic bladder
April 16th 2025

Neuromodulation device shows promising efficacy for neurogenic bladder

Hannah Clarke
Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.
3d rendered medically accurate illustration of prostate cancer | Image Credit: @ Sebastian Kaulitzki - stock.adobe.com
April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke
The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.
© 2025 MJH Life Sciences

All rights reserved.